Custom Search

Saturday, September 12, 2009

Classification of Air Cleanliness rely solely ISO 14644 1 ISO 14644 2 qualifying facility

Should a pharmaceutical manufacturer of sterile drug products which produces sterile drugs by aseptic processing rely solely on ISO 14644-1 and ISO 14644-2 when qualifying their sterile dosage form manufacturing facility?

As per the USFDA guidelines , a pharmaceutical manufacturer of sterile drug products who produces sterile drugs by aseptic processing should not rely soley on ISO 14644-1 and ISO 14644-2

This is generally not acceptable from a current good manufacturing practice (cGMP) perspective for a pharmaceutical manufacturer of sterile drug products which are produced by aseptic processing to rely solely on
ISO 14644-1 Part 1: Classification of Air Cleanliness ("14644-1") and
ISO 14644-2 Part 2: Specifications for Testing and Monitoring to Prove Compliance with ISO 14644-1 ("14644-2")

when qualifying their manufacturing facility.

Rather, a manufacturer of sterile drug products who produces sterile pharmaceuticals by aseptic processing should use these ISO standards in combination with applicable US FDA regulations, guidance and other relevant references to ensure a pharmaceutical facility is under an appropriate state of control. Consequently, appropriate measures augmenting ISO's recommendations (e.g., with microbiological data) would likely be expected for a firm to meet or exceed CGMP in a pharmaceutical facility.

US FDA answer to the question says that 14644-1 and 14644-2 have superseded Federal Standard 209E, Airborne Particulate Cleanliness Classes in Clean rooms and Clean Zones ("Federal Standard 209E").  In November 2001, the U.S. General Services Administration canceled Federal Standard 209E.
While not US FDA regulations or US FDA guidance, the Agency believes 14644-1 and 14644-2 are useful in facilitating the international harmonization of industrial air classification for non-viable particle cleanliness in multiple industries (e.g., computer, aerospace, pharmaceutical). 

As such, US FDA adopted these particle cleanliness ratings in the 2004 guidance for industry Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice.  However, due to the unique aspects of producing sterile drug products by aseptic processing (e.g., microbiological issues) an aseptic processing manufacturer should not rely solely on 14644-1 and 14644-2 when qualifying their facility.
We have written many articles on cgmp , sterile pharmaceutical manufacturing , we have provided all pharmaceutical SOPS , and all documents over this website.

We encourage you to subscribe to this website by entering your email ID , we send our articles by email to you as and when this website is updated.Regulatory affairs in pharmaceutical industry

Following are some of articles which;will be useful for you in further understanding of aspects of sterile dosage form manufacturing

Pharmaceutical Validation

Cleen Room Classification

Pharmaceutical Industry

Pharmaceutical Manufacturing

Clinical Trials

Media fill

Regulatory Affairs in Pharmaceutical Industry

No comments:

How to successfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.

1.You should write your Email ID in the box provided and push the subscribe button

2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Check our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.

Enter your email address get our articles by email whenever this website is updated

Delivered by FeedBurner

Join the list of our readers from Universities ,Research and
Development centers Pharmaceutical Companies from all over the world.

Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: Website:
Copyright © 2008-2020 all rights reserve